Donal Kyne
About Donal Kyne
Donal Kyne is a Senior R&D Engineer at Boston Scientific, specializing in the development of Transcatheter Aortic Valve Replacement (TAVR) technology. He holds a Bachelor's degree in Biomedical Engineering from the National University of Ireland, Galway.
Company
Donal Kyne currently works at Boston Scientific, a global leader in the development of medical devices. Specializing in providing innovative medical solutions, Boston Scientific is known for its products and services across a wide range of medical specialties. Donal has been associated with Boston Scientific in various capacities since 2015.
Title
Donal Kyne holds the position of Senior R&D Engineer at Boston Scientific. His role involves contributing to research and development, with a focus on progressing innovations in the medical device sector. Donal has been in this role since 2021.
Education and Expertise
Donal Kyne earned his Bachelor of Engineering (BE) in Biomedical Engineering from the National University of Ireland, Galway, where he studied from 2011 to 2015. He graduated with honors, showcasing his academic and technical excellence. Prior to his university education, he completed his high school at PCH Headford, earning his Leaving Certificate from 2005 to 2010.
Career Background
Donal Kyne started his career at Boston Scientific as a Graduate Engineer in 2015, working in Galway, County Galway, Ireland. He was then promoted to R&D Engineer I and continued his work at the same location from 2016 to 2018. Following that, he relocated to Minnesota, United States, where he served as R&D Engineer II from 2018 to 2021. He returned to Galway and took on his current role as Senior R&D Engineer in 2021.
Professional Contributions
Donal Kyne has made significant contributions to the development of Transcatheter Aortic Valve Replacement (TAVR) technology. His involvement spans all stages of the product life cycle, from initial research and design to testing and implementation. This work plays a crucial role in advancing minimally invasive treatments for heart valve disease.